An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

Completed · Phase 4

Conditions studied: Hypertension

In brief

This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.

Key facts

Study ID

NCT00403481

Run by

Daiichi Sankyo

People needed

192

Starts

2006-11-01

Expected to finish

2007-12-01

Last updated by the study team

2016-11-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with Type II diabetes that are on stable treatment with hypoglycemic agents
• Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mmHg but <200 mmHg and a MSDBP less than or equal to 114 mmHg following a 3 to 4-week single-blind placebo run-in period
• The difference in MSSBP between Visits 3 and 4 or between Visits 4 and 4X must be less than or equal to 10 mmHg
• Patients with a mean daytime (8AM - 4PM) SBP > 130 mmHg and less than or equal to 199 mmHg and a mean daytime DBP less than or equal to 114 as measured by an ambulatory blood pressure monitoring device (ABPM) following placebo run-in period
• If female, must have negative serum pregnancy test at screening and be either post-menopausal, had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study

You may not qualify if…

• History of stroke or transient ischemic attack (TIA) within the last one year
• History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
• Presence of overt proteinuria at screening
• Severe hypertension (DBP greater than or equal to 115 mmHg or SBP greater than or equal to 200 mmHg)
• Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome
• Type I or Type II diabetes requiring insulin
• Evidence of symptomatic resting bradycardia, congestive heart failure, or hemodynamically significant cardiac valvular disease
• Presence of heart block greater than first degree sinoatrial block, Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial fibrillation, or Atrial Flutter

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Mesa, Arizona, United States
• Study site — Searcy, Arkansas, United States
• Study site — Los Angeles, California, United States
• Study site — Roseville, California, United States
• Study site — Tustin, California, United States
• Study site — DeLand, Florida, United States
• Study site — Pembroke Pines, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Wichita, Kansas, United States
• Study site — Madisonville, Kentucky, United States
• Study site — Auburn, Maine, United States
• Study site — Baltimore, Maryland, United States
• Study site — Oxon Hill, Maryland, United States
• Study site — Jackson, Mississippi, United States
• Study site — Florissant, Missouri, United States
• Study site — Williamsville, New York, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Cincinnati, Ohio, United States
• Study site — New Talenwell, Tennessee, United States
• Study site — New Tazewell, Tennessee, United States
• Study site — Colleyville, Texas, United States
• Study site — Corpus Christi, Texas, United States
• Study site — Richardson, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.